Pliant Historical Income Statement
| PLRX Stock | USD 13.46 0.48 3.70% |
Historical analysis of Pliant Therapeutics income statement accounts such as Selling General Administrative of 29.4 M, Total Revenue of 1.5 M, Other Operating Expenses of 95.9 M or Research Development of 80.7 M can show how well Pliant Therapeutics performed in making a profits. Evaluating Pliant Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pliant Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Pliant Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pliant Therapeutics is a good buy for the upcoming year.
Pliant |
About Pliant Income Statement Analysis
Pliant Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Pliant Therapeutics shareholders. The income statement also shows Pliant investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Pliant Therapeutics Income Statement Chart
Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pliant Therapeutics. It is also known as Pliant Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Pliant Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pliant Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.At this time, Pliant Therapeutics' Interest Expense is fairly stable compared to the past year. Net Interest Income is likely to rise to about 20.2 M in 2024, despite the fact that EBIT is likely to grow to (152.1 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 272K | 4.7M | 20.5M | 21.5M | Net Interest Income | 272K | 3.9M | 19.2M | 20.2M |
Pliant Therapeutics income statement Correlations
Click cells to compare fundamentals
Pliant Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pliant Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ebit | (1.2M) | (41.6M) | (20.0M) | (122.5M) | (160.1M) | (152.1M) | |
| Net Income Applicable To Common Shares | (6.9M) | (41.5M) | (19.7M) | (123.3M) | (111.0M) | (105.4M) | |
| Net Interest Income | 816K | 478K | 272K | 3.9M | 19.2M | 20.2M | |
| Interest Income | 816K | 478K | 272K | 4.7M | 20.5M | 21.5M | |
| Depreciation And Amortization | 1.1M | 1.3M | 1.5M | 3.7M | 1.8M | 1.9M | |
| Selling General Administrative | 10.9M | 17.3M | 27.6M | 39.9M | 57.9M | 29.4M | |
| Total Revenue | 57.1M | 41.8M | 7.6M | 9.7M | 1.6M | 1.5M | |
| Other Operating Expenses | 58.3M | 83.5M | 27.6M | 136.9M | 185.7M | 95.9M | |
| Operating Income | (1.2M) | (41.6M) | (20.0M) | (127.2M) | (184.1M) | (174.9M) | |
| Net Income From Continuing Ops | (631K) | (41.5M) | (97.3M) | (123.3M) | (155.3M) | (147.5M) | |
| Research Development | 47.4M | 66.2M | 77.5M | 96.9M | 127.8M | 80.7M | |
| Ebitda | (118K) | (40.3M) | (18.5M) | (118.8M) | (158.2M) | (150.3M) | |
| Total Operating Expenses | 58.3M | 83.5M | 27.6M | 136.9M | 185.7M | 95.9M | |
| Reconciled Depreciation | 1.1M | 1.3M | 1.5M | 1.8M | 1.8M | 1.5M | |
| Income Before Tax | (631K) | (41.5M) | (19.7M) | (123.3M) | (161.3M) | (153.3M) | |
| Total Other Income Expense Net | 600K | 112K | 272K | 3.9M | 22.8M | 23.9M | |
| Net Income | 185K | (39.7M) | (17.9M) | (121.5M) | (161.3M) | (153.3M) | |
| Income Tax Expense | (816K) | (1.8M) | (1.8M) | (1.8M) | 1.7M | 1.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.